ORIC Pharmaceuticals Inc (STU:4TZ)
€ 9.4 0.2 (2.17%) Market Cap: 670.50 Mil Enterprise Value: 407.74 Mil PE Ratio: 0 PB Ratio: 2.30 GF Score: 42/100

Oric Pharmaceuticals Inc at AACR-NCI-EORTC Virtual International Conference Transcript

Oct 07, 2021 / 01:00PM GMT
Release Date Price: €16.4 (-1.20%)
Operator

Good day, and thank you for standing by, and welcome to the ORIC Pharmaceuticals Business Update Conference Call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Dominic Piscitelli, Chief Financial Officer. Please go ahead.

Dominic G. Piscitelli
ORIC Pharmaceuticals, Inc. - CFO

Good morning, and welcome to the ORIC Pharmaceuticals Business Update, AACR-NCI-EORTC Conference Call. This morning, we issued a press release highlighting initial clinical and translational data from our ongoing Phase Ib trial of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer as well as preclinical data on ORIC-114 in HER2-positive breast cancer.

You may find the press release posted on the Investor page of oricpharma.com. We have per-recorded our prepared remarks, after which we will host a live Q&A session. So please bear with us if we have any technical difficulties.

Before we begin, starting on Slide 2. During this conference call, we will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot